Biohaven Ltd. Depreciation
Biohaven Ltd. (BHVN) reported Depreciation of $621.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-08-10
- Biohaven Ltd. depreciation for the quarter ending 2026-06-30 was $621.00K, a 41.42% decline year-over-year.
- Biohaven Ltd. depreciation for the quarter ending 2026-03-31 was $708.00K, a 30.25% decline year-over-year.
- Biohaven Ltd. depreciation for the quarter ending 2025-12-31 was $960.00K, a 4.48% decline year-over-year.
- Biohaven Ltd. depreciation for the quarter ending 2025-09-30 was $1.10M, a 10.50% increase year-over-year.
- Biohaven Ltd. depreciation for fiscal 2025 was $4.14M, a 5.53% increase from fiscal 2024.
- Biohaven Ltd. depreciation for fiscal 2024 was $3.92M, a 16.44% increase from fiscal 2023.
- Biohaven Ltd. depreciation for fiscal 2023 was $3.37M, a 147.54% increase from fiscal 2022.
- Biohaven Ltd. depreciation for fiscal 2022 was $1.36M, a 102.23% increase from fiscal 2021.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|
| 2026-06-30 | $621.00K 10-Q · filed 2026-08-10 | $1.33M 10-Q · filed 2026-08-10 | $2.29M derived: sum of 3 quarters · filed 2026-08-10 | $3.39M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $708.00K 10-Q · filed 2026-05-04 | $1.67M derived: sum of 2 quarters · filed 2026-05-04 | $2.77M derived: sum of 3 quarters · filed 2026-05-04 | $3.83M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $960.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $2.06M derived: sum of 2 quarters · filed 2026-03-02 | $3.13M derived: sum of 3 quarters · filed 2026-08-10 | $4.14M 10-K · filed 2026-03-02 |
| 2025-09-30 | $1.10M 10-Q · filed 2025-11-10 | $2.17M derived: sum of 2 quarters · filed 2026-08-10 | $3.18M 10-Q · filed 2025-11-10 | $4.18M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $1.06M 10-Q · filed 2026-08-10 | $2.08M 10-Q · filed 2026-08-10 | $3.08M derived: sum of 3 quarters · filed 2026-08-10 | $4.08M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $1.01M 10-Q · filed 2026-05-04 | $2.02M derived: sum of 2 quarters · filed 2026-05-04 | $3.02M derived: sum of 3 quarters · filed 2026-05-04 | $4.00M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $2.00M derived: sum of 2 quarters · filed 2026-03-02 | $2.98M derived: sum of 3 quarters · filed 2026-03-02 | $3.92M 10-K · filed 2026-03-02 |
| 2024-09-30 | $1.00M 10-Q · filed 2025-11-10 | $1.98M derived: sum of 2 quarters · filed 2025-11-10 | $2.92M 10-Q · filed 2025-11-10 | $3.87M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $977.00K 10-Q · filed 2025-08-11 | $1.92M 10-Q · filed 2025-08-11 | $2.87M derived: sum of 3 quarters · filed 2026-03-02 | $3.72M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $941.00K 10-Q · filed 2025-05-12 | $1.89M derived: sum of 2 quarters · filed 2026-03-02 | $2.75M derived: sum of 3 quarters · filed 2026-03-02 | $3.55M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $948.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $1.80M derived: sum of 2 quarters · filed 2026-03-02 | $2.60M derived: sum of 3 quarters · filed 2026-03-02 | $3.37M 10-K · filed 2026-03-02 |
| 2023-09-30 | $857.00K 10-Q · filed 2024-11-12 | $1.66M derived: sum of 2 quarters · filed 2024-11-12 | $2.42M 10-Q · filed 2024-11-12 | $3.06M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $800.00K 10-Q · filed 2024-08-09 | $1.56M 10-Q · filed 2024-08-09 | $2.21M derived: sum of 3 quarters · filed 2025-03-03 | $2.44M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $764.00K 10-Q · filed 2024-05-09 | $1.41M derived: sum of 2 quarters · filed 2025-03-03 | $1.64M derived: sum of 3 quarters · filed 2025-03-03 | $1.92M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $643.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $873.00K derived: sum of 2 quarters · filed 2025-03-03 | $1.15M derived: sum of 3 quarters · filed 2025-03-03 | $1.36M 10-K · filed 2025-03-03 |
| 2022-09-30 | $230.00K 10-Q · filed 2023-11-14 | $509.00K derived: sum of 2 quarters · filed 2023-11-14 | $718.00K 10-Q · filed 2023-11-14 | $890.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $279.00K 10-Q · filed 2023-07-31 | $488.00K 10-Q · filed 2023-07-31 | $660.00K derived: sum of 3 quarters · filed 2024-02-29 | $832.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $209.00K 10-Q · filed 2023-05-12 | $381.00K derived: sum of 2 quarters · filed 2024-02-29 | $553.00K derived: sum of 3 quarters · filed 2024-02-29 | |
| 2021-12-31 | $172.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $344.00K derived: sum of 2 quarters · filed 2024-02-29 | $673.00K 10-K · filed 2024-02-29 | |
| 2021-09-30 | $172.00K 10-Q · filed 2022-11-09 | $501.00K 10-Q · filed 2022-11-09 | ||
| 2020-12-31 | $72.00K 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |